Abstract:Background: Cisplatin (CDDP), a widely used chemotherapeutic agent against hepatocellular carcinoma (HCC), faces severe resistance and hepatotoxicity problems which can be alleviated through combination therapy. Purpose: The objective of this study was to develop a pH-dependent calcium carbonate nano-delivery system for the combination therapy of CDDP with oleanolic acid (OA). Methods: A microemulsion method was employed to generate lipid coated cisplatin/oleanolic acid calcium carbonate nanoparticles (CDDP/OA-LCC NPs), and the loading concentration of CDDP and OA was measured by atomic absorption spectroscopy and HPLC respectively.Transmission electron microscopy (TEM) was used to examine the nanoparticles morphology while its pH dependent release characteristics were investigated through in vitro release study. Cellular uptake was examined through a fluorescence microscopy. Apoptotic assays and western blot analysis were conducted to explore the synergistic apoptotic effect of OA on CDDP against HCC cells. The hepatoprotective of OA for CDDP was evaluated through H&E staining. Results: TEM analysis revealed nanoparticles spherical shape with an average particle size of 206±15 nm, and the overall entrapment efficiency was 63.70%±3.9%. In vitro drug release study confirmed the pH-dependent property of the formulation, with the maximum CDDP release of 70%±4.6% at pH 5.5, in contrast to 28%±4.1% CDDP release at pH 7.4. Annexin V-FITC/PI assay and cell cycle analysis confirmed that CDDP and OA synergistically promoted greater HepG2 cells apoptosis for the CDDP/OA-LCC NPs as compared to their individual free drug solutions and NPs-treated groups. Western blot analysis also proved that CDDP/OA-LCC NPs induced the apoptosis by enhancing the proapoptotic protein expressions through downregulating P13K/AKT/mTOR pathway and upregulating p53 proapoptotic pathway. OA helped CDDP to overcome the resistance by downregulating the expression of proteins like XIAP, Bcl-2 via NF-κB pathway. OA also significantly alleviated CDDP-induced hepatotoxicity as evident from the decreased alanine transaminase, aspartate transaminase levels and histochemical evaluation. The possible mechanism may be related to the Nrf-2 induction via its antioxidant mechanism to maintain the redox balance and reduction in CYP2E1 activity which can lead to ROS-mediated oxidative stress. Conclusion: These results suggest that CDDP/OA-LCC NPs have promising applications for co-delivering CDDP and OA to synergize their anti-tumor activity against HCC and to utilize OA’s protective effect against CDDP-induced hepatotoxicity.

Oleanolic acid-NO donor-platinum(II) trihybrid molecules: Targeting cytotoxicity on hepatoma cells with combined action mode and good safety

ONS-donor Ligand Based Pt(II) Complexes Display Extremely High Anticancer Potency Through Autophagic Cell Death Pathway.

Oleanolic Acid-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles for Enhancing Chemotherapy to Liver Cancer.

Synergism of Cisplatin-Oleanolic Acid Co-Loaded Calcium Carbonate Nanoparticles on Hepatocellular Carcinoma Cells for Enhanced Apoptosis and Reduced Hepatotoxicity

Antitumor Platinum(Ii) Complexes Containing Platinum-Based Moieties of Present Platinum Drugs and Furoxan Groups As Nitric Oxide Donors: Synthesis, Dna Interaction, and Cytotoxicity

A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment

Dinuclear Platinum(II) Complexes with Bone-Targeting Groups as Potential Anti-Osteosarcoma Agents.

Homo- and Heteroleptic Pt(II) Complexes of ONN Donor Hydrazone and 4-Picoline: A Synthetic, Structural and Detailed Mechanistic Anticancer Investigation

Synthesis and biological evaluation of cholic acid-conjugated oxaliplatin as a new prodrug for liver cancer

Synthesis and antitumor activity of cis-platinum (II) type complexes containing alkoxylethoxylacetate groups

Novel Cisplatin-Type Platinum Complexes and Their Cytotoxic Activity

Synthesis and antitumor activity of α,β-unsaturated carbonyl moiety- containing oleanolic acid derivatives targeting PI3K/AKT/mTOR signaling pathway

Anticancer Potency of Platinum(Ii) Complexes Containing Both Chloride Anion and Chelated Carboxylate As Leaving Groups

Synthesis of Oleanolic Acid-Dithiocarbamate Conjugates and Evaluation of Their Broad-Spectrum Antitumor Activities

Epigenetic Platinum Complexes Breaking the "Eat Me/Don't Eat Me" Balance for Enhanced Cancer Chemoimmunotherapy

Design, Preparation and Studies Regarding Cytotoxic Properties of Benzyl Oleanates

Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism

Study on the Cytotoxic Activity of Platinum(ii) Complexes of (1 R ,2 R )- N 1 -Cyclopentyl-1,2-cyclohexanediamine with Substituted Malonate Derivatives

Preparation and in vitro cytotoxicity of oxaliplatin derivatives with chiral amino acid as the carrier group

A novel benzothiazole-based mononuclear platinum(II) complex displaying potent antiproliferative activity in HepG-2 cells via mitochondrial-mediated apoptosis

Study on the cytotoxic activity of platinum(II) complexes of (1R,2R)-N(1)-cyclopentyl-1,2-cyclohexanediamine with substituted malonate derivatives.